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Background: Non-steroidal anti-inflammatory drugs (NSAIDs) are used routinely to control pain and inflammation
after surgery in dogs. Robenacoxib is a new NSAID with high selectivity for the cyclo-oxygenase (COX)-2 isoform of
COX. The objective of this study was to evaluate the efficacy and tolerability of robenacoxib for the management of
peri-operative pain and inflammation associated with soft tissue surgery in dogs. The study was a prospective,
randomized, blinded, positive-controlled, non-inferiority, multi-center clinical trial. A total of 174 dogs undergoing
major soft tissue surgery were included and randomly allocated in a 2:1 ratio to receive either robenacoxib
(n = 118) or the positive control, meloxicam (n = 56). Each dog received an initial dose subcutaneously prior to
surgery (robenacoxib 2 mg/kg, meloxicam 0.2 mg/kg), followed by daily oral doses (robenacoxib 1–2 mg/kg,
meloxicam 0.1 mg/kg) for 12 days (range 10–14) after surgery. Pain and inflammation were assessed subjectively
using the Glasgow Composite Pain Scale (GCPS) by clinicians as the primary end point and additional evaluations
by the clinicians and animal owners as secondary endpoints.
Results: Both treatments provided similar pain control, with no significant differences between groups for any
efficacy variable using non-parametric analyses (Mann–Whitney U test). In no dog was analgesic rescue therapy
administered. Non-inferior efficacy of robenacoxib compared to meloxicam was demonstrated statistically for the
primary and all secondary endpoints using parametric analysis of variance, although the data were not normally
distributed even after log transformation. For the primary endpoint (reciprocal of the modified GCPS score), the
relative efficacy of robenacoxib/meloxicam was 1.12 with a 95% confidence interval of 0.97-1.29.
Both treatments were well tolerated and did not affect buccal mucosal bleeding time.
Conclusion: A treatment regimen of robenacoxib by subcutaneous injection followed by oral tablets had good
tolerability and non-inferior efficacy compared to meloxicam for the management of peri-operative pain and
inflammation associated with soft tissue surgery in dogs.
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Soft tissue surgical procedures in the dog are associated
with post-operative pain and peri-operative analgesia is
therefore recommended in many cases [1,2]. The duration
of pain control required varies between cases, but in some
instances is needed for seven days or longer [1]. The most
frequently used analgesics in dogs are opioids and non-
steroidal anti-inflammatory drugs (NSAIDs) [2]. The
introduction of newer NSAIDs which are selective inhibi-
tors of the cyclooxygenase (COX)-2 isoform of COX
(COX-2) should permit relief of pain and inflammation
whilst minimizing the adverse effects of non-selective
COX inhibitors in causing gastrointestinal tract damage
and interfering with blood clotting pathways [3].
Robenacoxib is a new NSAID with several properties of
interest for use in dogs undergoing surgery, including a
fast onset of action and the availability of both injection
and oral formulations [4]. Robenacoxib has a high safety
index in healthy dogs, which is attributed to its pharma-
codynamic and pharmacokinetic properties [5]. First,
robenacoxib is highly selective for COX-2 in dogs, and at
recommended dosages inhibits COX-2 while sparing
COX-1 [4,6]. Second, robenacoxib is cleared rapidly from
the central body compartment, but persists at sites of
inflammation [3,7]. The efficacy and tolerability of ro-
benacoxib has been demonstrated in dogs undergoing
orthopedic surgery [8].
In this study, the efficacy and tolerability of robenacoxib
were evaluated in dogs undergoing soft tissue surgery.
Since other NSAIDs are already registered in the
European Union (EU) for this indication, and widely used,
the study was a non-inferiority comparison to a positive
control, meloxicam. Meloxicam was selected as it is regis-
tered in the EU for the reduction of post-operative pain
and inflammation following soft tissue (and orthopedic)
surgery after a single injection pre-surgery, used exten-
sively, and its efficacy is proven for soft tissue surgery pain
in dogs [9-11]. The hypothesis of the study was that
robenacoxib would have non-inferior efficacy and toler-
ability compared to meloxicam.
Methods
Experimental design
The study was a prospective, randomized, parallel-group,
blinded, multi-center clinical trial conducted at 16 FrenchTable 1 Study schedule
Time (T) T0 T1 T1 +
Examination number/event 1 (initial visit) Extubation 2
Drug treatment Subcutaneous dose ** - -
Blood sample number for clinical
chemistry and hematology
1 - -
* Each dog was dosed orally once daily up to Day 12 (range 10–14) when the stitch
** Administered prior to surgery, close to the time of induction of anesthesia.and 9 German veterinary practices. The study schedule is
shown in Table 1. The study was approved by the French
and German regulatory authorities and Novartis com-
mittees taking into account scientific, ethical and animal
welfare guidelines. The investigation was conducted in
compliance with Good Clinical Practice (VICH GL9,
CVMP:VICH/595/98, 2000).
Animals
All owners gave written informed consent for their dogs
to be included in the study. The inclusion criteria com-
prised dogs aged ≥ 6 weeks, either gender, any breed,
weighing between 2.5 and 80 kg, scheduled to undergo
major soft tissue surgery. Exclusion criteria comprised
dogs: known to be pregnant or lactating; with severe con-
comitant disorders (gastro-intestinal tract, kidney or liver)
that may have interfered with the evaluation of response
to treatment; which received local or systemic NSAIDs or
opioids within 24 hours, or corticosteroids within 30 days,
prior to inclusion in the study. Exclusion criteria after in-
clusion and first dosing were: concomitant disorders that
could interfere with evaluation of response to treatment
(e.g. trauma); forbidden concomitant treatment; adverse
events requiring cessation of treatment.
Randomization and treatment allocation
Dogs were allocated randomly to the two treatment
groups in a 2:1 ratio using computer generated ran-
domization lists. The 2:1 ratio was used to obtain data in
more dogs receiving robenacoxib and was predicted to
cause only a modest (approximately 10%) reduction in
statistical efficiency compared to a 1:1 ratio. Case alloca-
tion was stratified according to investigator and antici-
pated duration of surgery at two levels, < 1 hour and >
1 hour.
Test articles and blinding
Dogs in group 1 received robenacoxib (OnsiorW 20 mg/
mL Solution for Injection, OnsiorW 5 or 20 mg Tablets,
Novartis Santé Animale, Huningue, France) at a dosage of
2 mg/kg subcutaneously as an initial dose on day 0, and
then 1–2 mg/kg orally once daily starting on day 1 for
12 days (range 10–14 days). The treatment time was se-
lected since previous work indicated that pain can persist
for 10–14 days after soft tissue surgery in dogs [1]. The1 h T1 + 2 h T1 + 4 h T1 + 8 h T1 + 24 h* (Day 1) Day 12*
3 4 5 6 7
- - - First oral dose Final oral dose
- - - 2 3
es were removed.
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no specific instructions regarding feeding. Co-admini-
stration of OnsiorW tablets with the entire daily ration in
dogs leads to a slight (26%) reduction in bioavailability
compared to administration without food [12].
Group 2 dogs were administered meloxicam (Me-
tacamW 5 mg/mL solution for injection, Labiana Life
Sciences S.A., Terrassa, Spain and MetacamW oral sus-
pension, Boehringer Ingelheim GmbH, Ingelheim/Rhein,
Germany) at a dosage of 0.2 mg/kg by subcutaneous injec-
tion on day 0, and then 0.1 mg/kg orally mixed with food
once daily starting on day 1 for up to 12 days (range 10–
14 days).
As robenacoxib and meloxicam formulations differed,
blinding was maintained by the “double-investigator tech-
nique”: one investigator, the clinician, was responsible for
clinical assessments and another, the dispenser, was re-
sponsible for treatment administration, prescription and
compliance control. Owners were not blinded to treat-
ment group.
Concomitant treatments
Drugs which could affect efficacy assessments were
disallowed, including: analgesics (opioids and α2-agonists),
other NSAIDs, corticosteroids, macrolides and tetracy-
clines. Opioids were not used as premedication as this was
not routine practice in France and Germany at the time
the study was conducted. However rescue analgesic ther-
apy (of any type) was permitted at any time if the clinician
judged it was necessary. Since use of analgesic therapy
was allowed for animal welfare reasons, and was not a
specific predefined efficacy endpoint, no specific criteria
were defined in the protocol when rescue therapy should
be used. Standard parameters relating to anesthetic pre-
medication, induction, maintenance and recovery were
recorded.
Efficacy assessment
Investigators were instructed that the same clinician (a
veterinarian) should make all efficacy assessments for all
cases at each site, whenever possible. The frequency of
exemptions to this rule was not assessed. The clinicians
were trained on the efficacy scoring methods before the
start of the study with the objective to standardize assess-
ments. However no validation, for example no assess-
ment of intra and inter-observer variation, was made.
The primary endpoint for efficacy comprised the
Glasgow Composite Pain Scale (GCPS) [13], assessed by
the clinician at seven examination times (T, hours) as in-
dicated in Tables 1 and 2: T1 (extubation), T1 + 1 h, T1
+ 2 h, T1 + 4 h, T1 + 8 h, T1 + 24 h and day (D)12. For
the first 6 examinations all components (A1, A2, B, C,
D1 and D2) of the scale were recorded. For the final
examination at D12, parts B, C, D1 and D2 wererecorded. Part B (mobility) could not be assessed in 21
dogs at early time points. As it is not valid to compare
dogs for which data with mobility was scored or not
scored, the main primary endpoint for the study was the
“modified” GCPS score without part B (n = 153 dogs,
maximum score 20).
There were six secondary efficacy endpoints, as follows:
(1 and 2) Using Visual Analogue Scales (VAS) at seven
examination times (Table 1) the clinician assessed: (a)
pain at rest on a scale ranging from 0 (no pain) to 100
(severe pain manifested by vocalization, aggression,
refusal to allow examination); and (b) pain during
gentle palpation/manipulation of the affected limb/joint
on a scale ranging from 0 (no pain elicited) to 100
(severe pain manifested by vocalization, aggression,
refusal to allow examination) [14].
(3) Clinician’s global assessment of efficacy (overall pain
control) at T1 + 24 h on the scale 0 = excellent,
1 = good, 2 = fair, 3 = poor.
(4) Clinician’s assessment of inflammation, using a VAS,
and based on joint/limb swelling, local heat, redness or
paresis, ranging from 0 (no inflammation) to 100
(major inflammation) on D12.
(5 and 6) Owner’s assessment of the dog daily from D1
to D12 using scales for: (a) demeanor and (b) mobility.
The scores were: 0 = normal and 1–4 for slight (1),
moderate (2), marked (3) or severely (4) modified
demeanor or impaired mobility. Mobility could not be
assessed in all dogs.Plasma cortisol concentration
Venous blood samples (1 mL) were collected into tubes
containing EDTA for measurement of plasma cortisol
concentrations at the times T0 (before surgery), T1
(extubation), T1 + 1 h, T1 + 2 h, T1 + 4 h and T1 + 8 h
(Table 1). Plasma samples were stored at −20°C prior to
analysis. Cortisol was measured by radio-immunoassay
using a commercial kit (IM-1841, Immunotech, Marseille,
France) at the National Veterinary School of Toulouse,
France. Within-day and day-to-day precisions were less
than 14% and the accuracy was within the range 93-109%.
The limit of quantification of the assay was 10 ng/mL.Tolerability assessment
The tolerability of administered treatments was assessed
from reported adverse events, clinical examination, pain at
injection, clinical chemistry, hematology and buccal mu-
cosal bleeding time. The clinicians and dog owners were
informed that two NSAIDs were being tested, and that ad-
verse effects of NSAIDs affect most frequently the gastro-
intestinal tract, kidney and liver. No specific assessment
was made of sedation. Pain at the time of injection (T0)
Table 2 The Glasgow Composite Pain Scale (GCPS)* used
by the clinicians to assess the dogs
Part Circumstance Assessment and Scale
A1 Dog in kennel Vocalization: Is the dog:
[0] quiet
[1] crying or whimpering
[2] groaning
[3] screaming
A2 Attention to wound area: Is the dog:
[0] ignoring any wound or painful area
[1] looking at wound or painful area
[2] licking wound or painful area
[3] rubbing wound or painful area
[4] chewing wound or painful area
B Dog out of
kennel on lead
Mobility: When the dog rises/walks is it:
[0] normal
[1] lame
[2] slow or reluctant
[3] stiff
[4] it refuses to move
C Response
to touch









Demeanor: Is the dog:
[0] happy and content or happy and bouncy
[1] quiet
[2] indifferent or non-responsive to surroundings
[3] nervous or anxious or fearful
[4] depressed or non-responsive to stimulation




[3] hunched or tense
[4] rigid
* Parts A, B, C and D were performed sequentially at the first 6 examination
times listed in Table 1. For examination 7 on Day 12, only parts B, C and D
were used.
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(no pain) to 3 (severe pain).
Venous blood samples (5 mL) were collected at three
times (T0, T1 + 24 h and D12, Table 1) for measurement
of variables including serum activities of alanineaminotransferase, alkaline phosphatase, aspartate amino-
transferase, gamma glutamyltransferase and concentra-
tions of creatinine, total protein and urea. Venous blood
samples (2 mL) were collected into EDTA at the same
times for measurement of hematology variables includ-
ing red blood cell, white blood cell and differential white
blood cell counts, hematocrit and hemoglobin concen-
tration. Buccal mucosal bleeding times were measured at
times T0 and T1 + 24 h.
Statistical analyses
Statistical tests were performed using SASW Software, Ver-
sion 8.2 (Cary, NC, US). All tests were performed two-
sided on a 5% level of significance. The main analyses
were conducted on the intention-to-treat population
(i.e. all randomized animals). The study was planned for a
minimum of 150 dogs (100 receiving robenacoxib and 50
receiving meloxicam). The sample size was calculated for
80% power in the non-inferiority analysis of the primary
endpoint (GCPS scores) using data from a pilot study. For
summary statistics, non-parametric and analysis of vari-
ance (ANOVA) statistical tests, missing values were im-
puted using the last observation carried forward method
(LOCF). The LOCF method was not used for repeated
measures ANOVA (RMANOVA), which was used to
analyze most efficacy endpoints. For the primary endpoint,
the GCPS scores, data were missing from a total of 4 dogs
(2 with robenacoxib, 2 with meloxicam).
Initial comparability tests
Demographic and baseline data were compared between
groups using the Mann–Whitney U test for ordinal
(e.g. body weight, effective duration of surgery) or bina-
ry data (e.g. sex), and with the Kruskal-Wallis test for
non-binary nominal data (e.g. combination of sex and
neutered status).
Efficacy variables
Efficacy measures and plasma cortisol concentrations
were analyzed statistically after log transformation using
ANOVA for variables with a single time point post-
treatment or RMANOVA if there were multiple time
points, as for most variables. The initial RMANOVA
model included the following variables: treatment group,
time, time/treatment interaction, baseline value (where
applicable), foreseen duration of the surgery, duration of
intubation, time between administration of test treatment
and extubation, sex, neutered status, body weight, age,
wakening time, country and type of surgery. Variables
(except treatment group) were removed progressively
from the model if P > 0.3.
Non-inferiority was defined if the 95% confidence inter-
val of the efficacy of robenacoxib divided by that of
meloxicam was greater than the pre-defined threshold of
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that the lower limit of the 95% confidence interval for
(1/mean score robenacoxib)/(1/mean score meloxicam)
needed to completely lie above 0.80.
Since most efficacy variables were not normally distri-
buted even after log transformation (P < 0.05 using the
Shapiro-Wilk test), groups were also compared using
the non-parametric Mann–Whitney U test in addition to
the ANOVA/RMANOVA analyses.
Clinical chemistry, hematology and bleeding time
As normality of these data was not proven, non-
parametric methods were applied. The Mann–Whitney U
test was used to compare the two groups before surgery,
after surgery, and the change between before and after
surgery. In addition, data before surgery and after surgery
were compared using the Wilcoxon paired-samples test,
separately for each group.
Adverse events
The incidence of adverse events in the two groups was
compared with the Fisher Exact test.
Results
Animals
A total of 174 client owned dogs were recruited from clin-
ical cases scheduled to undergo major soft tissue surgery.
Unless stated all reported results refer to the “intention-
to-treat” population, which consisted of all 174 dogs
which were randomized into one of the two groups, and
for which at least one post-treatment result was available.
The “per-protocol population” consisted of 166 dogs,
since eight dogs had major protocol deviations due to ad-
ministration of forbidden concomitant therapies. The
maximum number of dogs assessed by any one investiga-
tor was 23 (13% of the total).
There were no significant differences between groups in
the pre-surgery variables or surgery data except for dur-
ation of surgery which was significantly longer (P = 0.037)
in the robenacoxib group (Table 3). It was concluded that
the two groups were adequately balanced at baseline.
Case allocation was stratified according to investigator
and anticipated duration of surgery. Numbers of dogs in
the robenacoxib and meloxicam groups were respectively
87 and 44 for predicted duration < 1 hour, and 31 and 12
for > 1 hour. Differences were not significant (P = 0.57).
Test treatments
All dogs received a single subcutaneous injection of
robenacoxib or meloxicam prior to surgery. The targeted
subcutaneous dosage of robenacoxib was 2.0 mg/kg. Ac-
tual mean (range) dosages received were 2.00 (0.40 - 2.40)
mg/kg. The targeted subcutaneous dosage of meloxicamwas 0.20 mg/kg, whilst actual mean (range) dosages were
0.21 (0.15 - 0.50) mg/kg.
After surgery, dogs received follow-up treatment with
oral robenacoxib or meloxicam.
The targeted oral dosage of robenacoxib was 1–2 mg/kg
administered once daily for 10–14 days. Mean (range) ad-
ministered dosages were 1.39 (0.86 -2.16) mg/kg for a me-
dian (range) of 12 (0–15) days. The targeted oral dosage
of meloxicam was 0.1 mg/kg. Mean (range) dosages
administered were 0.10 (0.09 - 0.11) mg/kg for 12
(0–14 days). A total of 10 (8%) dogs in the robenacoxib
group and 6 (11%) in the meloxicam group were dosed or-
ally for shorter than the minimum 10 days defined in the
protocol, due to owner mistake or withdrawal of the dog
from the study.
Rescue therapy and concomitant treatments
Although clinicians were authorized to provide rescue
therapy at any time after surgery if needed, no dog
received such therapy. Concomitant therapies included
anesthesia drugs permitted in the protocol. Premedicants
(number of cases) included: no drug (42), acepromazine
(75), diazepam (41), diazepam and atropine (7), diazepam
and glycopyrollate (4), acepromazine and glycopyrollate
(3), acepromazine and atropine (1), and atropine (1).
Anesthesia was induced with either thiopentone (123) or
propofol (51), and maintained with either halothane (92)
or isoflurane (82). There were no significant differences
between groups.
Additional allowed concomitant treatments were pri-
marily fluids (131) and injectable (103) or oral (104) anti-
biotics, with no differences between groups. The principal
antibiotics were amoxicillin and cephalexin.
Eight dogs (five in the robenacoxib group, three in the
meloxicam group) were administered a total of eight
disallowed drugs, as follows: doxycycline (1), spiramycin
+metronidazole (3), spiramycin +metronidazole + pred-
nisolone (1), ketamine (1), carprofen (1) and dexame-
thasone (1). With the exception of cases receiving
spiramycin +metronidazole, all were administered as a
single dose.
Efficacy endpoints
The primary endpoint was the “modified” GCPS score
without part B (n = 153 dogs) since the mobility score (B)
could not be assessed in 21 dogs. However similar results
were obtained for the GCPS score with and without part
B (Tables 4 and 5). Pain was well controlled in most cases
in the post-operative period as indicated by mean modi-
fied GCPS scores less than 5.0 for dogs of both groups
(maximum score = 20, Figure 1). Pain was most apparent
on palpation/manipulation of the affected area rather than
at rest (Figures 2 and 3). Scores were maximal at 1 hour
and thereafter decreased slowly. For the owner
Table 3 Demographic and surgery variables. Data are mean (SD) or number of dogs (%)
Variable Robenacoxib Meloxicam Total P value*
Number of dogs 118 56 174
Age (years) 5.9 (3.9) 5.2 (4.1) 5.7 (3.9) 0.20
Body weight (kg) 20.8 (12.3) 19.0 (11.1) 20.2 (11.9) 0.42
Sex and neutered status
Male not neutered 14 (11.9%) 8 (14.3%) 22 (12.6%) 0.37
Female not neutered 87 (73.7%) 40 (71.4%) 127 (73.0%)
Male neutered 5 (4.2%) 0 (0%) 5 (2.9%)
Female neutered 12 (10.2%) 8 (14.3%) 20 (11.5%)
Pre-surgery pain (VAS)
▪ At rest 2.0 (5.4) 1.7 (2.3) 1.9 (4.6) 0.21
▪ At palpation/manipulation 5.2 (10.2) 4.2 (6.3) 4.9 (9.2) 0.64
Type of surgery**
▪ Ovariectomy 37 (31%) 22 (39%) 59 (34%) 0.31
▪ Ovario-hysterectomy 28 (24%) 10 (18%) 38 (22%) 0.44
▪ Mammary chain excision 30 (25%) 15 (27%) 45 (26%) 0.85
▪ Gastro-intestinal surgery 5 (4%) 0 (0%) 5 (3%) 0.18
▪ Genito-urinary surgery 5 (4%) 2 (4%) 7 (4%) 1.0
▪ Thoracic surgery 1 (1%) 0 (0%) 1 (1%) 1.0
▪ Other soft tissue surgery 22 (19%) 10 (18%) 32 (18%) 1.0
Duration of surgery (hours) 0.85 (0.52) 0.68 (0.35) 0.79 (0.48) 0.037
Duration of intubation (hours) 1.4 (0.77) 1.2 (0.60) 1.3 (0.73) 0.20
Time between injection of robenacoxib or meloxicam and extubation (hours) 1.6 (0.81) 1.4 (0.63) 1.5 (0.76) 0.18
Duration of oral dosing (days) 11.3 (22.2) 10.9 (3.0) - 0.92
Data are mean (SD) or number of dogs (%).
* Significance of differences between treatment groups (Kruskal-Wallis or Mann–Whitney U tests).
** Some dogs underwent two surgeries during the same anesthesia.
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scores were recorded on day 1 and decreased progres-
sively thereafter (Figures 4 and 5).
Overall group means and group comparison P values
using the non-parametric Mann–Whitney U test are
presented for all endpoints in Table 4. For both the pri-
mary and all six secondary efficacy endpoints, there were
no significant differences between the robenacoxib and
meloxicam groups.
In the non-inferiority analysis (Table 5), non-inferiority
of robenacoxib relative to meloxicam was present, as indi-
cated by lower confidence interval values >0.80, for the
primary endpoint and all six secondary endpoints. How-
ever, in spite of log transformation of the data, the models
deviated significantly from a normal distribution for all
endpoints except for inflammation. For the primary end-
point, the modified GCPS score (without part B), the rela-
tive efficacy of robenacoxib/meloxicam was 1.12 with a
95% confidence interval of 0.97-1.29. In the RMANOVA
model, for the modified GCPS score, significant effects
of the following covariates persisted in the final model:time (P < 0.0001); country (P < 0.007) and body weight
(P = 0.020).
Similar results were obtained using the “per-protocol”
population, with non-inferiority proven for the primary
endpoint and five of the six secondary endpoints (data not
shown). For the primary endpoint (modified GCPS score)
using the “per-protocol population”, the relative efficacy of
robenacoxib/meloxicam was 1.08 with a 95% confidence
interval of 0.91-1.28.
In some other studies, rescue therapy was adminis-
tered automatically if a minimum GCPS score was
reached, for example ≥5 for the modified score (without
part B) or ≥6 for the unmodified score (with part B)
[15,16]. Therefore, although not planned in the protocol,
we evaluated the number of dogs in each group which
had defined scores. P values were calculated with the
Fisher Exact test. The number (percentage of total) dogs
with a modified GCPS score (without B) ≥5 was 47
(39.8%) for robenacoxib and 26 (46.4%) for meloxicam
(P = 0.42); ≥6 was 29 (24.6%) for robenacoxib and 22
(39.3%) for meloxicam (P = 0.052); ≥7 was 24 (20.3%) for
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and ≥8 was 17 (14.4%) for robenacoxib and 12 (21.4%)
for meloxicam (P = 0.28).
The number (percentage of total) dogs with an unmodi-
fied GCPS score (with B) ≥6 was 60 (50.8%) for
robenacoxib and 35 (62.5%) for meloxicam (P = 0.19); ≥7
was 47 (39.8%) for robenacoxib and 29 (51.8%) for
meloxicam (P = 0.15); and ≥8 was 40 (33.9%) for ro-
benacoxib and 23 (41.1%) for meloxicam (P = 0.40).
Plasma cortisol concentration
Plasma cortisol concentrations prior to dosing and up to
8 hours after extubation are presented in Table 6. Sig-
nificant and quantitatively similar increases compared
with pre-anesthesia values were obtained in both groups
(P < 0.0001, Wilcoxon test). Log-transformed cortisol con-
centrations fulfilled normal distribution assumptions in
the ANOVA (P = 0.30) but not RMANOVA (P = 0.0001)
analysis. Using ANOVA, there were no significant differ-
ence between the robenacoxib and meloxicam groups
(P = 0.20). Non-inferiority was demonstrated in the
ANOVA analysis, the mean quotient (robenacoxib/
meloxicam) of the reciprocal of cortisol concentrations
was 0.92 (95% confidence interval, 0.84-1.02). There were
significant model effects in the ANOVA for countryTable 4 Efficacy endpoints
Variable Group Estimate St
Primary endpoint
Modified GCPS score (without B) Robenacoxib 1.65
Meloxicam 1.97
Unmodified GCPS score (with B) Robenacoxib 2.35
Meloxicam 2.79
Secondary endpoints
Pain at rest Robenacoxib 2.62
Meloxicam 3.30
Pain at palpation/manipulation Robenacoxib 4.34
Meloxicam 5.29
Global efficacy score Robenacoxib 0.45
Meloxicam 0.56
Global inflammation score Robenacoxib 1.11
Meloxicam 1.76
Owner assessment: demeanor Robenacoxib 0.10
Meloxicam 0.10
Owner assessment: mobility Robenacoxib 0.10
Meloxicam 0.05
GCPS = Glasgow Composite Pain Scale.
Data are ANOVA or RMANOVA estimates for group means, standard errors and con
RMANOVA and Mann–Whitney U tests.(P = 0.027), baseline (P <0.0001), duration of intubation
(P = 0.0021) and type of surgery (P = 0.0046).
Tolerability
A total of 17 of the 118 dogs (14%) receiving robenacoxib
and 12 of the 56 dogs (21%) receiving meloxicam had
reported adverse events (P = 0.26). Most adverse events
were classified as benign or moderate. The most frequent
reports concerned the gastrointestinal tract (vomiting,
diarrhea, dark or soft stools). One death occurred in a
12 year old dog in the meloxicam group due to pancrea-
titis. This event was classified as unrelated to treatment.
Five adverse events were classified as severe, of which two
were judged to be unrelated to treatment and two classi-
fied as unknown relationship to treatment. Both of the
latter were in the robenacoxib group: one comprised
dermatitis in the surgical area and the second involved
hematoma linked to the surgery. A fifth case, also in the
robenacoxib group, presented with vomiting 15 minutes
after extubation and was classified as possibly linked to
treatment. This dog received metoclopramide and recov-
ered completely without alteration to robenacoxib dosing.
Pain at the site of subcutaneous injection was minimal,
being reported as absent in 109 (92%) and present in 9
(8%) of dogs receiving robenacoxib, and absent in 47andard
error








0.12 1.42 1.90 0.12 0.29
0.18 1.63 2.35
0.17 2.03 2.71 0.13 0.72
0.26 2.31 3.34
0.31 2.06 3.28 0.20 0.54
0.49 2.43 4.39
0.53 3.39 5.50 0.28 0.71
0.84 3.82 7.19
0.06 0.33 0.58 0.28 0.22
0.09 0.39 0.76
0.25 0.66 1.67 0.12 0.59
0.42 1.04 2.74
0.02 0.07 0.13 0.96 0.62
0.02 0.06 0.14
0.03 0.05 0.16 0.17 0.098
0.03 −0.01 0.12
fidence intervals. P values for group comparisons are from ANOVA or













1/Modified GCPS score (without B) 1.12 0.08 0.97* 1.29 0.12 <.0001**
1/Unmodified GCPS score (with B) 1.13 0.09 0.96* 1.32 0.13 0.0005**
Secondary endpoints
1/Pain at rest 1.19 0.16 0.91* 1.55 0.20 <.0001**
1/Pain at palpation/manipulation 1.18 0.18 0.87* 1.58 0.28 0.0049**
1/Global efficacy score 1.08 0.07 0.94* 1.23 0.28 <.0001**
1/Global inflammation score 1.31 0.23 0.93* 1.85 0.12 0.058
1/Owner assessment: demeanor 1.00 0.02 0.95* 1.05 0.96 0.010**
1/Owner assessment: mobility 0.95 0.03 0.89* 1.02 0.17 0.010**
GCPS = Glasgow Composite Pain Scale.
All data were log transformed for the ANOVA/RMANOVA analyses.
Values are reciprocals of scores, thus values >1.00 indicate lower scores (higher efficacy) for robenacoxib versus meloxicam.
* Non-inferiority of robenacoxib to meloxicam shown (lower confidence limit >0.80).
** Data were not normally distributed after log transformation.
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loxicam. Differences between groups were not significant
(P = 0.17).
There were no changes in buccal mucosal bleeding
time at T1 + 24 h compared to prior to surgery (T0) with
either drug. Mean ± SD bleeding times at T0 and T1 +
24 h were respectively 131 ± 63 and 131 ± 56 min with
robenacoxib (P = 0.80), and 143 ± 65 and 122 ± 59 min
with meloxicam (P = 0.091). There was no significant dif-
ference between groups at baseline (P = 0.91) or at
24 hours (P = 0.20).
For clinical chemistry and hematology variables, there
were isolated incidents of statistical significance atTime after extubation

























Figure 1 Modified Glasgow Composite Pain Scale (GCPS) score
(without part B) assessed by clinicians at defined times after
extubation. The score is a numerical rating scale ranging from 0
(minimum) to 20 (maximum). Data are mean and SD.24 hours which were judged not be relevant clinically:
white cell counts higher with robenacoxib and plasma
urea concentrations higher with meloxicam. There were
no significant differences between groups for change
from baseline analyses.
Discussion
The main conclusion of this study is that a treatment regi-
men of a single subcutaneous injection of robenacoxib be-
fore surgery, followed by once daily administration of
robenacoxib tablets for 12 days, was well tolerated and had
statistically non-inferior efficacy in comparison with me-
loxicam for the management of pain and inflammation as-
sociated with soft tissue surgery in dogs. A variety ofTime after extubation



















Figure 2 Pain at rest at defined times after extubation. Pain was
assessed by clinicians using a 0–100 mm visual analogue scale. Data
are mean and SD.
Time after extubation




























Figure 3 Pain at palpation or mobilization at defined times
after extubation. Pain was assessed by clinicians using a 0–100 mm
visual analogue scale. Data are mean and SD.
Time after extubation (days)

























Figure 5 The dog’s mobility on days 1 to 14 after surgery. The
mobility was assessed by owners using a 0–4 numerical rating scale.
Data are mean and SD.
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http://www.biomedcentral.com/1746-6148/9/92methods are available for the clinical assessment of pain in
animals. In this study, the primary endpoint was the clini-
cian’s assessment of the GCPS [13]. At the time of initi-
ation of the study, weighing factors for the indices had not
yet been published [1,17], and therefore unweighted results
are reported. The results of the primary endpoint were
supported by six secondary endpoints. No significant dif-
ferences between groups were observed using the non-
parametric Mann–Whitney U test for the primary and all
six secondary efficacy variables. Non-inferior efficacy of
robenacoxib compared to meloxicam was also demon-
strated statistically for both the primary and all six second-
ary efficacy using ANOVA and RMANOVA analyses.
However the reliably of those ANOVA and RMANOVA
analyses is uncertain since the data deviated significantly
from a normal distribution, in spite of log transformation,Time after extubation (days)


























Figure 4 The dog’s demeanor on days 1 to 14 after surgery.
The demeanor was assessed by owners using a 0–4 numerical rating
scale. Data are mean and SD.for all endpoints except inflammation. In addition the
GCPS is the sum of ordinal or ranking scales and is not an
interval scale, and therefore in principle non-parametric
statistics should be used. However to our knowledge no
suitable non-parametric methods exist for non-inferiority
analysis, which was the primary objective of the study.
Therefore a combination of non-parametric and paramet-
ric tests was used, and using both approaches provides
greater confidence that robenacoxib had non-inferior effi-
cacy compared to meloxicam.
The major limitations of the study are discussed below.
First, although the dogs were assessed reasonably inten-
sively by the clinician in the first 24 hours after surgery
while hospitalized, the follow-up from day 2 onwards was
sparse and consisted mainly of daily assessments of the
dog’s demeanor and mobility by the owner. A final examin-
ation was made by the clinician when the stitches were re-
moved at day 12. Second, although the clinicians were
masked to treatment groups, via the use of a dispenser, the
dog owners were not blinded. For this and other reasons,
the primary endpoint of the study was based on theTable 6 Plasma cortisol concentrations (ng/mL) prior to
and at times following surgery
Time (h) Robenacoxib Meloxicam
Mean SD Mean SD
Pre-surgery 69.8 41.62 76.1 52.19
0 136.6 53.90 125.9 51.13
1 159.8 74.76 140.4 60.87
2 145.7 76.30 132.9 74.47
4 101.6 60.00 98.3 47.23
8 88.3 46.78 85.1 44.03
Mean (post-surgery) 116.0 51.21 108.5 42.26
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sessment was made of sedation, and therefore we do not
know if sedation could have confounded the efficacy as-
sessments. However signs consistent with sedation were
only reported in one dog (“apathy” in the robenacoxib
group) and to our knowledge neither meloxicam nor
robenacoxib have any reported sedative properties. No
sedative effects were reported with administration of high
dosages of robenacoxib (40 mg/kg daily for 1 month) to
dogs [5]. Fourth, although the clinicians were authorized to
provide rescue therapy at any time after surgery if needed,
no dog received such therapy. Other authors have auto-
matically administered rescue therapy to dogs if a mini-
mum score was reached, for example a modified GCPS
score (without part B) ≥5 or an unmodified score (with
part B) ≥6 [15,16]. Although not planned in the protocol of
this study, we determined that the number (percentage of
total) of dogs with a modified GCPS score ≥5 was 47
(39.8%) in the robenacoxib group and 26 (46.4%) in the
meloxicam group (P = 0.42). For the unmodified score
(with part B), the number of dogs with a score ≥6 was 60
(50.8%) in the robenacoxib group and 35 (62.5%) in the
meloxicam group (P = 0.19). Therefore different investiga-
tors may have concluded that many of the dogs in the
study required additional analgesia. The relatively high
number of dogs with GCPS scores above the thresholds
defined above is probably due to the fact that opiates were
not used in any dog. Optimal control of post-operative
pain requires mixed therapy with NSAIDs and opioids [2].
Fifth and last, the limitations of non-inferiority studies
using positive controls are well-known [18]. In this case,
however, use of a placebo would have raised ethical and re-
cruitment issues in this study conducted in France and
Germany since a number of NSAIDs are registered for
peri-operative use in dogs in the EU and are widely used.
Meloxicam was selected as the positive control since it is
registered and extensively used in dogs, and its efficacy ad-
ministered by injection prior to surgery in dogs undergoing
soft tissue surgery has been proven via superiority to
butorphanol or placebo [9-11]. To our knowledge there
exist no published data on the efficacy of oral meloxicam
to treat post-operative pain for 12 days in dogs, as used in
our study. The efficacy of meloxicam versus placebo was
demonstrated for up to 72 hours after ovariohysterectomy
[11]. However, oral 0.1 mg/kg meloxicam had significant
efficacy in the urate synovitis model in dogs [19]. Therefore
we conclude that there is satisfactory evidence for the effi-
cacy of meloxicam to control pain and inflammation in
dogs undergoing soft tissue surgery, and thus it was a suit-
able positive control for this study. However in none of the
above mentioned published studies was the GCPS used, as
in our study. In optimally designed non-inferiority studies,
the methods and outcome measures should be similar to
those used in the original studies of the active control [18].Superiority of deracoxib versus placebo, and firocoxib ver-
sus a negative control, was reported recently from two
studies in dogs undergoing soft tissue using similar
methods to our study including use of the GCPS [20,21].
The frequency of rescue therapy in those studies with treat-
ment as a single dose pre-surgery followed by 2 days post-
surgery was higher [deracoxib 2/16 (12.5%), placebo 9/16
(56.25%), firocoxib (16.4%), negative control (50.6%)] than
in our study with robenacoxib (0%) or meloxicam (0%).
A feature of our study was the choice of a non-inferiority
threshold (δ) value of 0.20. The δ value should reflect the
largest margin that is clinically acceptable. In fact the re-
sults show that non-inferior efficacy of robenacoxib to the
positive control would also have been achieved if we had
defined δ = 0.05 for the primary endpoint i.e. with a
maximum of 5% difference in modified GCPS scores. Fur-
thermore, robenacoxib had numerical superiority to me-
loxicam for the primary endpoint (relative efficacy 1.12)
and for five of the secondary endpoints (range 0.95 to
1.31). Therefore, the data support the conclusion of non-
inferior efficacy.
In both groups plasma cortisol concentrations were ap-
proximately doubled after surgery, relative to pre-anes-
thesia values, and had not returned to control values at the
last time point of 8 hours after extubation. The extent and
duration of the observed rise in cortisol concentrations are
consistent with published literature in which increases by
factors of 2 to 3 lasting 2 to 4 hours are reported [22-24].
There were no significant differences between the treat-
ment groups in cortisol concentrations. In a previous
study, no change in plasma cortisol concentrations was
noted with meloxicam in dogs undergoing mammary gland
excision [25].
Robenacoxib and meloxicam were both well tolerated in
this study. Although adverse effects were reported in 29 of
174 dogs, most were assessed as mild or benign and classi-
fied as either not or only possibly treatment related. The
adverse effects reported most frequently were occasional
vomiting and loose stools. There were also no biologically
relevant changes in hematology and biochemistry variables,
and no significant change in buccal mucosa bleeding time,
with either robenacoxib or meloxicam. The latter result is
not surprising for robenacoxib, since it does not inhibit
COX-1 at recommended dosages in dogs [4,6] or affect
buccal bleeding time at therapeutic or elevated dosages in
healthy dogs [5]. Buccal bleeding time also did not increase
with meloxicam, although this might be expected from the
fact that 0.3 mg/kg meloxicam by injection significantly in-
hibits COX-1 in dogs [4]. No significant differences in buc-
cal mucosa bleeding time were noted previously in dogs
receiving meloxicam compared to placebo in dogs under-
going abdominal surgery [9,10,26].
The rationale for the development of highly COX-2 se-
lective NSAIDs such as robenacoxib is that they should
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lective NSAIDs such as meloxicam [7]. The finding of no
significant differences in tolerability between robenacoxib
and meloxicam in this study is not surprising, however,
since the study was underpowered to detect differences in
safety parameters, with only 174 dogs and a relatively short
treatment duration (maximum 16 days). In addition we did
not include specific safety investigations, for example gas-
troscopy, which might have revealed differences in toler-
ability as noted previously for other NSAIDs [27].
Conclusions
In this clinical trial, a treatment regimen of robenacoxib,
consisting of a single subcutaneous injection prior to sur-
gery (2 mg/kg) followed by once daily administration of
tablets post-operatively at 1–2 mg/kg for 12 days, had good
tolerability and non-inferior efficacy compared to me-
loxicam for the control of pain and inflammation in dogs
undergoing soft tissue surgery.
Availability of supporting data
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